Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group, Inc. develops and commercializes regenerative biomaterial products for wound care, burn and surgical applications. Its updates center on placental allografts and related advanced wound care technologies, including AMNIOFIX, CHORIOFIX and G4Derm Plus, as the company adds product configurations, distribution rights and clinical evidence for complex wound management.
Company news also covers operating results for the Wound and Surgical businesses, reimbursement-driven market conditions, cost-reduction actions, investor presentations, conference participation and capital actions such as share repurchase authorization.
MiMedx Group, Inc. (Nasdaq: MDXG) reported fourth quarter net sales of $68.5 million and full-year net sales of $248.2 million for 2020, down from $299.3 million in 2019. The company faced a net loss of $49.3 million for the year, influenced by $59.5 million in investigation and restatement expenses. MiMedx anticipates a 10% increase in adjusted net sales for 2021, contingent on regulatory approvals, particularly for its biologic AmnioFix® Injectable. The company will host a conference call on March 9, 2021, to discuss these results.
MiMedx Group, Inc. (Nasdaq: MDXG) announced its participation in two upcoming virtual investor conferences. The H.C. Wainwright Global Life Sciences Conference will feature a presentation on March 10, 2021, viewable on-demand starting at 2:00 PM ET. Key management participants include Timothy R. Wright and Peter M. Carlson. The Oppenheimer 31st Annual Healthcare Conference will include a fireside chat on March 16, 2021, at 3:50 PM ET, with Wright and Robert B. Stein, M.D., Ph.D. Webcast details for both conferences are available on the company’s website.
MiMedx Group, Inc. (Nasdaq: MDXG) announced it will report its financial results for the fourth quarter and full year ended December 31, 2020, after market close on March 8, 2021. A conference call and webcast will be held on March 9, 2021, at 9:30 AM ET with key executives discussing the results. MiMedx specializes in advanced wound care and therapeutic biologics, focusing on the development of human placental tissue allografts. They have distributed over two million allografts using their proprietary PURION process.
MiMedx Group (Nasdaq: MDXG) announced that CEO Timothy R. Wright and CFO Peter M. Carlson will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 17, 2021, at 3:30 PM ET. A live webcast of the event will be accessible via the Company's website and the conference site. A replay will be available for 90 days post-event. MiMedx specializes in advanced wound care and therapeutic biologics, developing human placental tissue allografts using patented processes.
MiMedx Group (Nasdaq: MDXG) announces CEO Timothy R. Wright and CFO Peter M. Carlson will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13 at 4:30 PM EST. Institutional investors wishing to connect with management can contact their J.P. Morgan representatives.
Interested parties can access the live webcast on the company's website, with a replay available for 30 days post-presentation. MiMedx specializes in advanced wound care, providing over two million allografts using its proprietary PURION® process.
MARIETTA, Ga., Jan. 4, 2021 – MiMedx Group (Nasdaq: MDXG) announced that CEO Timothy R. Wright and EVP Dr. Robert Stein will participate in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference from January 11-14, 2021. The chat will be pre-recorded and available on MiMedx's Investors webpage starting January 11 at 6:00 AM ET, accessible for 90 days. MiMedx is a leader in advanced wound care and therapeutic biologics, specializing in human placental tissue allografts using its proprietary PURION® process.
Prescience Point Capital Management has raised the price target for MiMedx Group Inc. (MDXG) to $31 per share. Prescience, a major shareholder with 6.5% ownership, highlights its analysis of the Amniofix injectable product currently in Phase 2b trials for knee osteoarthritis and Phase 3 for plantar fasciitis. Findings suggest Amniofix could be a revolutionary treatment, with potential for billions in annual sales. The firm anticipates FDA approval for knee OA and other indications, indicating substantial undervalue in current share prices.
MARIETTA, Ga., Dec. 07, 2020 - MiMedx Group, Inc. (Nasdaq: MDXG) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 4:30 PM EST. The company, known for its advanced wound care solutions, invites institutional investors to connect with management through J.P. Morgan representatives. A live webcast can be accessed on the company's website, with a replay available post-presentation. MiMedx specializes in human placental tissue allografts and has supplied over two million allografts using its proprietary processes.
MiMedx Group, Inc. (NASDAQ: MDXG) has appointed Jack Howarth as Senior Vice President of Investor Relations. With 25 years in public relations and financial communications, plus 40 years in the medical sector, Howarth aims to enhance the company’s visibility within the financial community. CEO Timothy R. Wright emphasized the need for effective communications as MiMedx seeks to expand its market leadership in advanced wound care. Howarth previously held significant roles in various pharmaceutical firms, including Antares Pharmaceuticals and King Pharmaceuticals.
MiMedx Group has announced that CEO Timothy R. Wright and CFO Peter M. Carlson will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference happening from December 1-3, 2020. A pre-recorded presentation will be available on the company's website starting November 25, 2020, at 5:00 PM Eastern Time, and will be accessible for 45 days. MiMedx specializes in advanced wound care and therapeutic biologics, particularly using PURION technology to produce human placental tissue allografts, having supplied over 2 million allografts to date.